EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis. J of Skin 2025, 9 (6), s633. https://doi.org/10.25251/jg65bt44.